The total return over the past 12 months is -43.02% vs. +16.94% for the S&P 500. So far it's up -25.53% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (43.02%) | (33.37%) | (32.02%) | (14.20%) | (9.24%) | (5.02%) |
| Total Return CAGR | (43.02%) | (33.37%) | (32.02%) | (14.20%) | (9.24%) | (4.48%) |
| Revenue CAGR | (3.16%) | +4.89% | +9.70% | +0.68% | +4.75% | +10.26% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | (27.21%) | (17.20%) | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Myriad Genetics, Inc. (MYGN)
| Year | Start price | End price | MYGN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.15 | $4.58 | (25.53%) | +14.51% | (40.04%) |
| 2025 | $13.71 | $6.15 | (55.14%) | +17.72% | (72.86%) |
| 2024 | $19.14 | $13.71 | (28.37%) | +24.89% | (53.26%) |
| 2023 | $14.51 | $19.14 | +31.91% | +26.19% | +5.72% |
| 2022 | $27.60 | $14.51 | (47.43%) | (18.17%) | (29.26%) |
| 2021 | $19.77 | $27.60 | +39.61% | +28.74% | +10.87% |
| 2020 | $27.23 | $19.77 | (27.40%) | +18.37% | (45.77%) |
| 2019 | $29.07 | $27.23 | (6.33%) | +31.22% | (37.55%) |
| 2018 | $34.35 | $29.07 | (15.37%) | (4.56%) | (10.81%) |
| 2017 | $16.67 | $34.35 | +106.06% | +21.70% | +84.36% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
